RESEARCH ARTICLE

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients

Jingxuan Wang, Kangping Lu, Ying Song, Shu Zhao, Wenjie Ma, Qijia Xuan, Dabei Tang, Hong Zhao, Lei Liu, Qingyuan Zhang*

Department of Medical Oncology, The Third Hospital of Harbin Medical University, Harbin, China

* zqywsci@163.com

Abstract

Background
Breast cancer patients treated with aromatase inhibitors (AIs) may experience musculoskeletal adverse events (MS-AEs). Several studies have confirmed that the RANKL/RANK/OPG signaling pathway plays a dominant role in bone health. Therefore, this study aimed to analyze the relationship between the serum levels of RANKL, OPG and their SNPs (single nucleotide polymorphisms) with AI-related MS-AEs.

Methodology and Principal Findings
Patients with early stage, hormone-sensitive breast cancer who were receiving AI therapy were enrolled. We included 208 cases with AI-related MS-AEs and 212 without (controls). The levels of estradiol, bone-turnover markers, multiple inflammatory cytokines, RANKL, OPG and lumbar spine BMD were measured, and questionnaires were completed. We analyzed 29 SNPs of RANKL, RANK and OPG using Sequenom MassARRAY assays and PCR-based TaqMan assays. The levels of bone-turnover markers and RANKL and the ratio of RANKL/OPG were higher in patients with AI-related MS-AEs than controls (all p < 0.05). A genetic assay showed that the RANKL SNP rs7984870 and OPG SNP rs2073618 were associated with AI-related MS-AEs. In patients with AI-related MS-AEs, rs7984870 CC and rs2073618 CC were risk genotypes. Carriers of the rs7984870 CC genotype were more likely to have a higher RANKL level and RANKL/OPG ratio than carriers of the GG genotype, and carriers of the rs2073618 CC genotype were more likely to have a lower OPG level and a higher RANKL/OPG ratio than carriers of the GG genotype (all p < 0.05). Moreover, risk genotypes were associated with higher levels of serum CTX and PINP and a lower lumbar spine BMD (all p < 0.05).
Conclusions and Significance
In conclusion, the RANKL and OPG risk genotypes synergize to negatively impact bone health and predispose breast cancer patients to AI-related MS-AEs.

Introduction
Tamoxifen has been the mainstay of endocrine therapy for more than 30 years. However, recent studies have indicated that aromatase inhibitors (AIs) are superior to the antiestrogen tamoxifen for improving the rates of disease-free survival and possibly overall survival in postmenopausal women with hormone receptor-positive breast cancer [1–3]. AIs profoundly reduce circulating estrogen levels in postmenopausal women by an additional 80–90% compared with tamoxifen. However, blocking estrogen synthesis is associated with a modest increase in deleterious effects on the musculoskeletal system, such as arthralgia, osteoporosis, and bone fractures [4], which are referred to as AI-related musculoskeletal adverse events (MS-AEs) [5,6]. MS-AEs are of particular importance among adverse events in early stage breast cancer patients. Because these patients may be cured and have a life expectancy in the decades, it is crucial to avoid the potential fractures and deformity associated with MS-AEs. Consequently, an understanding of the risks of disease progression and the therapeutic options available for the maintenance and restoration of their bone health is imperative for individual patients with early stage breast cancer.

Although no agents have received broad international regulatory approval for the prevention of AI-related MS-AEs, several interventions have demonstrated activity against aromatase inhibitor-induced bone loss and musculoskeletal symptoms, including denosumab, zoledronic acid and acupuncture [5–9]. Denosumab, a fully human monoclonal antibody against RANKL, has been approved for the treatment of osteoporosis in postmenopausal women in the United States (in the event that other therapies have failed or are contraindicated) and Europe. Subgroup analyses of a phase 3 study showed that twice-yearly administration of denosumab consistently increased BMD (bone mineral density) versus placebo at 12 and 24 months for nonmetastatic breast cancer patients receiving adjuvant aromatase inhibitor therapy [10].

Bones are continuously repaired in adults by well-organized cycles of bone resorption and formation, so-called “bone remodeling”. The RANKL/RANK/OPG signaling pathway plays an important role in the regulation of bone remodeling, osteoclast differentiation and osteolysis [11]. RANKL, a type II membrane protein of the tumor necrosis factor family (TNFSF11), is expressed on osteoblasts, stromal cells, activated T cells, B cells and megakaryocytes. Bone loss is mediated by osteoclasts, whose formation, function, and survival all depend on RANKL activity. Binding of RANK to RANKL on preosteoclasts and mature osteoclasts can promote the formation, activation, and survival of multinucleated osteoclasts during normal bone remodeling and a variety of pathologic conditions [12,13]. OPG, a decoy receptor for RANKL, protects bone from excessive resorption via binding to RANKL and thereby preventing it from binding to RANK [12,13]. The genes encoding these proteins are well known as candidate genes that influence the maintenance of bone health [14,15].

In our previous study, we reported two ESR1 SNPs, rs2234693 and rs9340799 were associated with AIs-related MS-AEs. Based on these findings, we selected 29 SNPs of RANKL, RANK and OPG in the present study to identify whether they were associated with MS-AEs in women receiving adjuvant AI therapy for early stage breast cancer. Furthermore, we performed studies to elucidate the potential functional basis for these associations.
Materials and Methods

Ethics statement
We obtained approval from the ethical board of the Third Hospital of Harbin Medical University, and all of the volunteers provided written informed consent prior to conducting this study.

Study participants
From August 2007 to March 2012, we recruited postmenopausal Chinese Han women with completely resected, stage I to III breast cancer in the Third Affiliated hospital of Harbin Medical University. Pathologically, all of the patients had estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive breast cancer. To be considered for enrollment, patients needed to be currently taking letrozole (2.5 mg/day) or anastrozole (1 mg/day) adjuvant therapy, and this regimen must have been taken for at least 1 year prior to the study. All indicated surgeries, radiation therapies, and chemotherapies for breast cancer treatment were completed before enrollment.

Patient definition for musculoskeletal adverse events
Because the patients received AI therapy, they had at least one of the following six symptoms of MS-AEs: joint pain, muscle pain, bone pain, arthritis, diminished joint function, or other musculoskeletal problems. Cases were required to have at least grade 3 toxicity according to the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events v3. Patients who had either of the following were excluded from the study: (1) any MS-AEs before they received AI therapy or (2) inflammatory, metabolic, or neuropathic arthropathies or surgery of an afflicted extremity during the preceding 6 months and were currently taking steroids (oral or injected) or narcotics.

Controls were breast cancer patients who were completely free of any MS-AEs after AI therapy and had not taken steroids (oral or injected) or narcotics for at least 6 months.

Patients and controls were matched for demographics, clinical characteristics and prior therapy. At the time of evaluation, rheumatologists reported the symptoms’ severity and impact on patient function, as well as the apparent association between symptoms and AI therapy (related or not related).

Measurements of BMD
The BMD of the lumbar spine (L1-4) was measured by dual energy X-ray absorptiometry (Lunar prodigy, GE Healthcare, United Kingdom). BMD was reported as an absolute value (g/cm2) and as a T score, which represents the number of standard deviations from a young, sex- and ethnic group-specific reference mean. According to the World Health Organization’s (WHO) definitions, T scores were used as the basis for diagnosis as follows: normal bone mineral density, T score greater than -1; osteopenia, T score less than or equal to -1 but greater than -2.5; and osteoporosis, T score less than or equal to -2.5.

Specimen collection and DNA extraction
Whole blood was obtained for genotyping and measuring inflammatory markers. All samples were examined blindly by laboratory personnel. Serum was obtained by centrifugation at 1000 × g for 5 min at room temperature. DNA samples were extracted from peripheral blood samples of patients and controls using the AxyPrep Blood Genomic DNA Miniprep Kit.
Assessment of serum estradiol, bone turnover markers, inflammatory markers and OPG/RANK/RANKL

Serum estradiol (E2) was measured using an electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics GmbH). Two bone turnover markers, carboxy terminal telopeptide (CTX) and procollagen type I N-terminal propeptide (PINP), were measured in serum samples via ECLIA (Roche diagnostics GmbH).

Levels of inflammatory markers, including interferon gamma (IFN$\gamma$), tumor necrosis factor alpha (TNF$\alpha$), interleukin-1 (IL1), interleukin-4 (IL4), interleukin-6 (IL6), interleukin-10 (IL10), interleukin-12 (IL12), interleukin-17 (IL17) and interleukin-23 (IL23), were measured.

The concentrations of the serum inflammatory markers OPG, RANK and RANKL in supernatants were assessed using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).

SNP selection

Known SNPs of OPG, RANK and RANKL were selected using “Tagger” (http://www.broadinstitute.org/mpg/tagger/server.html) and data from the International HapMap Project (http://snp.cshl.org/). A total of 27 SNPs of the three genes of interest (7 for OPG, 16 for RANK, 4 for RANKL) were selected based on the following criteria: (1) their status was validated in a Han Chinese population in Beijing; (2) their tag SNPs were in linkage disequilibrium with all SNPs in the HapMap dataset with a minor allele frequency $\geq$ 5%; and (3) they were identified after running the Tagger program in an aggressive tagging mode using 2- and 3-marker haplotypes with $r^2$ and LOD thresholds set at 0.8 and 3.0 respectively.

The SNPs rs2277438 in the RANKL gene and rs2073618 in the OPG gene were also selected because they are associated with bone health [16,17]. rs2073618 is a missense mutation of the OPG gene, while other 28 SNPs are located in the intron region of each gene.

Genotyping

Genotyping was performed by the Sequenom MassARRAY technology platform using iPLEX GOLD chemistry (Sequenom, San Diego, CA). Briefly, specific assays were designed using the MassARRAY AssayDesign software package with filtering of proximal SNPs and checking of specificity for PCR amplification and the subsequent primer extension reaction. SpectroTyper 4.0 was used to call genotypes automatically, followed by manual review.

As a secondary platform, PCR-based TaqMan assays (Applied Biosystems, Foster City, CA) were performed according to the manufacturer’s instructions, and the results were analyzed on the ABI Prism 7500 using Sequence Detection Software (Applied Biosystems Co. Ltd., USA). To confirm the accuracy of the genotyping results, 10% of the samples of each SNP were randomly selected to be tested twice by different lab personnel; the reproducibility was 100%.

Statistical analysis

The non-parametric Mann-Whitney U-test was used to compare case and control values for categorical data, and unpaired two-tailed t-tests were used for continuous data. The strength of pair-wise linkage disequilibrium (LD) ($r^2$) between two genetic polymorphisms was assessed using Haploview 4.1. Logistic regression analyses were used to estimate the odds ratios (OR), 95% confidence intervals (CI) and corresponding p values of alleles and genotypes, with OR
values above 1.0 indicating an increased risk. Data were analyzed using SPSS 19.0. A p value < 0.05 was considered to indicate statistical significance. For evaluating the Sequenom MassARRAY assay data of the 29 SNPs of RANK, RANKL and OPG, p values < 0.05 were defined as nominally significant, bonferroni correction for multiple testing was applied for the total number of SNPs in this study when assessing relationship between Minor Allele Frequency and individual SNPs (the corrected level of significance was p = 0.05/29 = 0.0017).

Results

Patient characteristics

We selected 208 patient cases who were referred for rheumatological evaluation because of the following six MS-AEs: joint pain, muscle pain, bone pain, arthritis, diminished joint function or worsened functional status during AI therapy. We then selected 212 matched controls who did not experience increased pain or worsened functional status during AI therapy. The baseline characteristics of patients in the AI-related MS-AEs group and control group are presented in Table 1. Serum estradiol, CTX, PINP, OPG, RANKL concentration and BMD prior to aromatase inhibitors treatments in the AI-related MS-AEs group and control group are presented in S1 Table.

Serum concentrations of estradiol, bone turnover markers, and multiple inflammatory markers

Serum concentrations of estradiol and bone turnover markers from patients in the AI-related MS-AEs group were compared with those of the controls (Table 2). As expected, both groups had an average estradiol level in the postmenopausal range. Mean estradiol levels were significantly lower in the AI-related MS-AEs group compared with the controls (8.98 ± 5.92 pg/ml vs. 11.23 ± 6.22 pg/ml; p = 3.16E-7).

Furthermore, we observed significant differences in the concentrations of CTX (231.1 ± 113.7 pg/ml vs. 219.8 ± 98.2 pg/ml; p = 8.46E-6) and PINP (357.1 ± 134.3 pg/ml vs. 332.6 ± 118.9 pg/ml; p = 3.64E-7) between cases and controls.

Among the cytokines with the greatest importance in inflammatory responses, pain and arthritis, we selected nine cytokines for further study (IFNγ, TNFα, IL1, IL4, IL6, IL10, IL12, IL17 and IL23). No significant differences were observed in any of these inflammatory factors between cases and controls.

Next, the serum concentrations of OPG and RANKL were analyzed in matched pairs of cases and controls (Fig 1). The serum OPG levels in the AI-related MS-AEs group were reduced compared with controls, although this difference was not significant. However, for breast cancer patients with AI-related MS-AEs, the level of RANKL (698.0 ± 62.6 pg/ml) and the ratio of RANKL/OPG (2.43 ± 0.22) were higher than the controls (RANKL: 502.1 ± 45.2 pg/ml, RANKL/OPG: 1.48 ± 0.14, p < 0.05).

Frequencies of genotypes and alleles

A total of 29 SNPs of the three genes were selected (8 for OPG, 16 for RANK, 5 for RANKL). The LD patterns of these three genes are shown in S1 Fig None of the genotyped SNPs had a minor allele frequency less than 5%. To ensure the quality control of genotyping results, samples that failed to be genotyped in the first round were genotyped a second time. As shown in Table 3, a lower prevalence of the rs7984870 minor allele was observed in breast cancer patients with AI-related MS-AEs (39.4%) than the controls (60.6%), and this association was significant (p = 3.07E-5, OR = 0.560, 95% CI: 0.425–0.736). The rs2073618 allele was associated with
AI-related MS-AEs in this study (p = 6.09E-4, OR = 1.623, 95% CI: 1.233–2.141). However, the other 27 SNPs of RANK, RANKL and OPG showed no significant differences between the case and control groups (p > 0.05).

Table 1. Subject characteristics of the patients in AI-related MS-AEs group and controls.

| Characteristic                  | Cases (n = 208) | Controls (n = 212) | p value |
|--------------------------------|-----------------|-------------------|---------|
| **Age (years)**                |                 |                   |         |
| ≥58                            | 102             | 107               | 0.769   |
| <58                            | 106             | 105               |         |
| Mean ± SD                      | 57.3 ±15.7      | 58.1 ±14.9        | 0.091   |
| **Treatment arm**              |                 |                   |         |
| Anastrozole                    | 68              | 72                | 0.783   |
| Letrozole                       | 140             | 140               |         |
| Median treatment time (months) | 24.9± 7.6       | 25.3± 8.2         | 0.145   |
| **ER/PR status**               |                 |                   |         |
| ER+/PR+                        | 133             | 140               | 0.653   |
| ER+/PR−                        | 58              | 60                |         |
| ER−/PR+                        | 17              | 12                |         |
| **Her-2 status**               |                 |                   | 0.978   |
| Negative                       | 142             | 145               |         |
| Positive                       | 66              | 67                |         |
| **Histological grade**         |                 |                   | 0.846   |
| I                              | 30              | 32                |         |
| II                             | 146             | 147               |         |
| III                            | 32              | 33                |         |
| **Years since menopause**      |                 |                   | 0.698   |
| ≥10                            | 65              | 70                |         |
| <10                            | 143             | 142               |         |
| **Median BMI (kgm², range)**   |                 |                   | 0.773   |
| ≥25                            | 105             | 110               |         |
| <25                            | 103             | 102               |         |
| **Prior chemotherapy**         |                 |                   | 0.580   |
| No                             | 66              | 62                |         |
| Yes                            | 142             | 150               |         |
| **Prior taxane treatment**     |                 |                   | 0.145   |
| No                             | 120             | 137               |         |
| Yes                            | 88              | 75                |         |
| **Prior tamoxifen treatment**  |                 |                   | 0.591   |
| No                             | 172             | 171               |         |
| Yes                            | 36              | 41                |         |
| **Prior radiation therapy**    |                 |                   | 0.894   |
| No                             | 67              | 67                |         |
| Yes                            | 141             | 145               |         |
| **Smoking**                    |                 |                   | 0.781   |
| No                             | 190             | 192               |         |
| Yes                            | 18              | 20                |         |

Note: SD = standard deviation; BMI = body mass index.

doi:10.1371/journal.pone.0133964.t001
We attempted to determine whether any of these SNPs may be functional using Sequenom MassARRAY assays. We then tested and verified these results using PCR-based TaqMan

Table 2. Serum concentrations of serum estradiol, bone turnover markers and inflammatory markers.

|                        | Cases (mean ± SD) | Controls (mean ± SD) | p value   |
|------------------------|-------------------|----------------------|-----------|
| E2 (pg/ml)             | 8.98 ± 5.92       | 11.23 ± 6.22         | 3.16E-7   |
| CTX (pg/ml)            | 231.1 ± 113.7     | 219.8 ± 98.2         | 8.46E-6   |
| PINP (pg/ml)           | 357.1 ± 134.3     | 332.6 ± 118.9        | 3.64E-7   |
| IFNγ (pg/ml)           | 318.7 ± 157.3     | 308.5 ± 155.1        | 0.076     |
| TNFα (pg/ml)           | 19.15 ± 4.17      | 18.71 ± 3.99         | 0.111     |
| IL1 (pg/ml)            | 77.32 ± 35.58     | 75.01 ± 23.60        | 0.332     |
| IL4 (pg/ml)            | 24.02 ± 5.90      | 24.94 ± 5.86         | 0.092     |
| IL6 (pg/ml)            | 5.95 ± 1.36       | 6.21 ± 1.94          | 0.115     |
| IL10 (pg/ml)           | 24.65 ± 3.99      | 24.32 ± 2.35         | 0.081     |
| IL12 (pg/ml)           | 2.46 ± 0.77       | 2.56 ± 0.85          | 0.255     |
| IL17 (pg/ml)           | 13.55 ± 5.42      | 12.67 ± 4.93         | 0.067     |
| IL23 (pg/ml)           | 894.1 ± 341.0     | 908.3 ± 386.2        | 0.075     |

Note: SD = standard deviation; E2 = estradiol; CTX: carboxy terminal telopeptide; PINP: procollagen type I N-terminal propeptide.

doi:10.1371/journal.pone.0133964.t002

Fig 1. RANKL and OPG expression in 420 breast cancer patients. A. Serum concentrations of RANKL and OPG. B. The ratio of RANKL/OPG. Cases: n = 208; Controls: n = 212. *p < 0.05.

doi:10.1371/journal.pone.0133964.g001
assays. Similar to the results of the MassARRAY assays, rs7984870 of RANKL and rs2073618 of OPG were associated with AI-related MS-AEs. As shown in Table 4, for the rs7984870 polymorphism, we observed a higher prevalence of the CC genotype and C allele ($p = 2.19 \times 10^{-4}$, OR = 1.801, 95% CI: 1.306–2.483; and $p = 3.07 \times 10^{-5}$, OR = 1.787, 95% CI: 1.359–2.351, respectively) in the AI-related MS-AEs group than the control group. Furthermore, the C allele of rs2073618 had a higher prevalence among breast cancer patients with AI-related MS-AEs ($p = 6.09 \times 10^{-4}$, OR = 1.623, 95% CI: 1.233–2.141), and genotype analysis also indicated a significant association between this SNP and the risk of AI-related MS-AEs (CC: $p = 7.95 \times 10^{-4}$, OR = 2.931, 95% CI: 1.624–5.288).

Table 3. Association between risk of AI-related musculoskeletal adverse events and 29 SNPs of RANK, RANKL and OPG.

| dbSNP      | Gene | Chr | Position | Location | cases | controls | OR         | 95%CI       | P value |
|------------|------|-----|----------|----------|-------|----------|------------|-------------|---------|
| rs12457042 | RANK | 18  | 58144433 | intron   | 0.151 | 0.146    | 1.042      | 0.713–1.524 | 0.847   |
| rs4941129  | RANK | 18  | 58151457 | intron   | 0.409 | 0.413    | 0.983      | 0.747–1.294 | 0.944   |
| rs7237982  | RANK | 18  | 58155233 | Intron   | 0.065 | 0.061    | 1.062      | 0.609–1.853 | 0.888   |
| rs7239261  | RANK | 18  | 58156026 | Intron   | 0.216 | 0.203    | 1.085      | 0.778–1.513 | 0.672   |
| rs12969154 | RANK | 18  | 58157123 | Intron   | 0.324 | 0.330    | 0.971      | 0.727–1.296 | 0.883   |
| rs4369774  | RANK | 18  | 58161428 | Intron   | 0.315 | 0.311    | 1.017      | 0.760–1.361 | 0.941   |
| rs12956925 | RANK | 18  | 58164620 | Intron   | 0.075 | 0.083    | 0.895      | 0.541–1.481 | 0.702   |
| rs11877530 | RANK | 18  | 58166915 | Intron   | 0.267 | 0.264    | 1.014      | 0.746–1.377 | 0.938   |
| rs11664594 | RANK | 18  | 58169186 | Intron   | 0.495 | 0.486    | 1.038      | 0.792–1.361 | 0.836   |
| rs12455775 | RANK | 18  | 58170830 | Intron   | 0.261 | 0.250    | 1.059      | 0.776–1.444 | 0.752   |
| rs8567270  | RANK | 18  | 58177985 | Intron   | 0.257 | 0.267    | 0.953      | 0.701–1.296 | 0.814   |
| rs7239667  | RANK | 18  | 58180218 | Intron   | 0.452 | 0.425    | 1.118      | 0.851–1.468 | 0.445   |
| rs4303637^ | RANK | 18  | 58182743 | Intron   | 0.363 | 0.398    | 0.862      | 0.652–1.139 | 0.319   |
| rs4941131  | RANK | 18  | 58191141 | Intron   | 0.313 | 0.318    | 0.973      | 0.727–1.302 | 0.882   |
| rs6567276  | RANK | 18  | 58195664 | Intron   | 0.315 | 0.297    | 1.087      | 0.811–1.458 | 0.601   |
| rs9646629  | RANK | 18  | 58202179 | Intron   | 0.377 | 0.394    | 0.933      | 0.706–1.232 | 0.671   |
| rs7984870  | RANK | 13  | 42044482 | Intron   | 0.394 | 0.606    | 0.560      | 0.425–0.736 | 3.07E-5# |
| rs9594782  | RANK | 13  | 42049186 | intron   | 0.120 | 0.116    | 1.046      | 0.687–1.590 | 0.835   |
| rs9566990  | RANK | 13  | 42062710 | intron   | 0.231 | 0.236    | 0.972      | 0.706–1.338 | 0.671   |
| rs9533166  | RANK | 13  | 42075169 | Intron   | 0.192 | 0.167    | 1.184      | 0.832–1.684 | 0.370   |
| rs2277438  | RANK | 13  | 42053168 | intron   | 0.255 | 0.222    | 1.200      | 0.873–1.650 | 0.292   |
| rs3102724  | OPG  | 8   | 120015988| intron   | 0.380 | 0.384    | 0.981      | 0.742–1.295 | 0.943   |
| rs1485286  | OPG  | 8   | 120019849| intron   | 0.423 | 0.448    | 0.903      | 0.687–1.187 | 0.487   |
| rs1485288  | OPG  | 8   | 120019969| intron   | 0.118 | 0.097    | 1.247      | 0.804–1.934 | 0.323   |
| rs3134058* | OPG  | 8   | 120023289| intron   | 0.454 | 0.448    | 1.024      | 0.780–1.345 | 0.890   |
| rs11573856 | OPG  | 8   | 120024176| intron   | 0.151 | 0.163    | 0.918      | 0.633–1.332 | 0.705   |
| rs3102728  | OPG  | 8   | 120025486| intron   | 0.125 | 0.118    | 1.069      | 0.706–1.617 | 0.833   |
| rs3134068  | OPG  | 8   | 120031840| intron   | 0.111 | 0.099    | 1.131      | 0.727–1.759 | 0.652   |
| rs2073618  | OPG  | 8   | 120033233| missense | 0.478 | 0.361    | 1.623      | 1.233–2.141 | 6.09E-4^ |

*Cases = 207, missing = 1
^controls = 211, missing = 1
# Significant after Bonferroni correction
doi:10.1371/journal.pone.0133964.t003
Moreover, the haplotypes CC of rs7984870 and CC of rs2073618 were risk genotypes; women with either risk genotype had a significantly higher risk of AI-related MS-AEs than patients without these genotypes (p = 5.77E-6, OR = 2.915, 95% CI: 1.817–4.677).

Correlation of risk genotypes with estradiol, bone turnover markers and BMD

Table 5 shows differences in the levels of estradiol, CTX, PINP and BMD in relation to the risk genotypes in patients with AI-related MS-AEs.

No significant differences were observed in serum estradiol levels based on the risk or no risk genotype. However, we observed a significant correlation between the expression of bone turnover markers and risk genotypes. Women with risk genotypes had significantly increased levels of serum CTX (rs7984870: 242.1 ± 98.1 pg/ml vs. 229.7 ± 86.8 pg/ml, p = 1.11E-6; rs2073618: 252.6 ± 99.5 pg/ml vs. 223.9 ± 84.3 pg/ml, p = 3.68E-9) and PINP (rs7984870: 371.6 ± 139.9 pg/ml vs. 336.3 ± 123.1 pg/ml, p = 1.50E-7; rs2073618: 369.1 ± 127.4 pg/ml vs. 325.0 ± 120.2 pg/ml, p = 5.09E-10) compared with women with no risk genotypes.

Compared with no risk genotypes, the rs2073618 CC risk genotype (0.987 ± 0.257 g/cm² vs. 0.801 ± 0.218 g/cm², p = 0.049) but not the rs7984870 CC risk genotype (0.975 ± 0.206 g/cm² vs. 0.806 ± 0.186 g/cm², p = 0.075) showed a significant reduction in BMD at the lumbar spine. However, women with either risk genotype of AI-related MS-AEs had a higher prevalence of osteoporosis (rs7984870: 30.2% vs. 9.4%, p = 0.026; rs2073618: 36.0% vs. 16.9%, p = 0.029) and osteopenia (rs7984870: 42.1% vs. 18.8%, p = 0.027; rs2073618: 40.0% vs. 20.3%, p = 0.034) than women with no risk genotypes.

As it showed in Table 6, we didn’t observe any correlation between the expression of bone turnover markers and risk genotypes in the controls.

The rs7984870 SNP may affect RANKL expression and RANKL/OPG ratio

Using ELISA, we sought to investigate whether plasma levels of soluble RANKL and the ratio of RANKL/OPG were associated with the rs7984870 genotype in breast cancer patients with...
AI-related MS-AEs. Interestingly, we found that soluble RANKL levels were higher in breast cancer patients with AI-related MS-AEs carrying the rs7984870 CC genotype (739.3 ± 66.6 pg/ml) than those carrying the GG genotype (642.2 ± 57.8 pg/ml, p < 0.05, Fig 2A). Additionally, carriers of the rs7984870 CC genotype were more likely to have a higher RANKL/OPG ratio (2.58 ± 0.21) than carriers of the GG genotype (2.14 ± 0.12, p < 0.05, Fig 2B).

The rs2073618 SNP may affect OPG expression and the ratio of RANKL/OPG

We subsequently tested whether the rs2073618 genotypes were correlated with OPG expression and the ratio of RANKL/OPG. Compared with the rs2073618 GG genotype (316.3 ± 43.7 pg/ml), carriers of the rs2073618 CC genotype had significantly lower OPG expression (282.2 ± 26.9 pg/ml, Fig 2C). Furthermore, carriers of the rs2073618 CC genotype were more likely to have a higher RANKL/OPG ratio (2.52 ± 0.18) than carriers of the GG genotype (2.30 ± 0.15, p < 0.05, Fig 2D).

Lumbar spine BMD measurements and its correlation to the ratio of RANKL/OPG

Fig 3A shows the absolute measurements of the lumbar spine BMD of the study population. Compared with the control group, a significant decrease in the BMD in the AI-related MS-AEs
The rates of osteoporosis, osteopenia and normal BMD in patients with or without AI-related MS-AEs based on the lumbar spine BMD T score are summarized in Fig 3B. Patients in the AI-related MS-AEs group had a higher prevalence of osteoporosis than the controls (27.4% vs. 8.5%, respectively, p < 0.05). In contrast, a normal BMD was more common in the control group. The prevalence of osteopenia was 37.0% in the AI-related MS-AEs group and 35.4% in the control group; however, this difference was not significant.

Furthermore, we investigated whether the lumbar spine BMD T score was correlated with the ratio of serum RANKL/OPG in the AI-related MS-AEs group (Fig 3C). As expected, we found that patients with osteopenia were far more likely to have a higher RANKL/OPG ratio than women with a normal BMD (2.35 ± 0.18 vs. 2.12 ± 0.15, respectively, p < 0.05). However, patients with osteoporosis were more likely to have a higher RANKL/OPG ratio compared with those with osteopenia (2.56 ± 0.25 vs. 2.35 ± 0.18, respectively, p < 0.05).

**Discussion**

Aromatase inhibitor therapy in postmenopausal women causes bone health problems, such as lower BMD, vitamin D insufficiency, arthralgia and fractures. AI-induced bone health problems are increasingly recognized as a clinically significant toxicity of AI therapy, but the mechanisms underlying the development of these problems remain unclear. One study found that denosumab was an effective agent for the management of AI-induced bone loss, with an

---

**Table 6. Differences of estradiol, CTX, PINP and BMD with risk genotype or no risk genotype in the control.**

| Genotype | Risk | No risk | P value |
|----------|------|---------|---------|
| rs7984870 CC | (n = 43) | (n = 59) | 0.777 |
| E2 (pg/ml) | 11.16 ± 5.98 | 11.30 ± 6.10 | 0.051 |
| CTX (pg/ml) | 222.2 ± 89.2 | 218.9 ± 88.6 | 0.168 |
| PINP (pg/ml) | 334.1 ± 125.8 | 331.0 ± 121.0 | |
| Lumbar spine BMD (g/cm²) | 0.975 ± 0.207 | 1.002 ± 0.225 | 0.772 |
| WHO-criteria | n (%) | n (%) | |
| Lumbar spine BMD T-score | | | |
| <-2.5 SD (Osteoporosis) | 5(11.6) | 5(8.5) | 0.597 |
| -2.5 SD—1.0 SD (Osteopenia) | 16(37.2) | 21(35.6) | 0.867 |
| ->1.0 SD (Normal) | 22(51.2) | 33(56.0) | 0.633 |
| rs2073618 CC | (n = 24) | (n = 83) | |
| E2 (pg/ml) | 11.21 ± 5.67 | 11.28 ± 5.89 | 0.900 |
| CTX (pg/ml) | 223.9 ± 95.9 | 219.5 ± 88.9 | 0.053 |
| PINP (pg/ml) | 335.2 ± 123.8 | 332.1 ± 118.5 | 0.230 |
| Lumbar spine BMD (g/cm²) | 0.968 ± 0.211 | 0.999 ± 0.245 | 0.775 |
| WHO-criteria | n (%) | n (%) | |
| Lumbar spine BMD T-score | | | |
| <-2.5 SD (Osteoporosis) | 3(12.5) | 7(8.4) | 0.545 |
| -2.5 SD—1.0 SD (Osteopenia) | 9(37.5) | 30(36.1) | 0.903 |
| ->1.0 SD (Normal) | 12(50.0) | 46(55.4) | 0.639 |

Note: E2 = estradiol; BMD = bone mineral density.

doi:10.1371/journal.pone.0133964.t006
adverse event profile similar to that of placebo [18]. Loss of bone mass resulting from treatment with aromatase inhibitors is not unusual. However, osteoporosis in such patients is typically diagnosed too late, usually after a fracture appears. Arthralgia, muscle pain, bone pain and other musculoskeletal problems are typically the early symptoms of AI-induced skeletal damage. Fortunately, most skeletal damage is reversible with early supplementation of vitamin D and calcium. Therefore, to evaluate methods for identifying high-risk individuals and improving AI-induced bone health, we selected patients who experienced at least one of the following six symptoms of MS-AEs: joint pain, muscle pain, bone pain, arthritis, diminished joint function, or other musculoskeletal problems.

The ESCEO working group recommends treatment with denosumab and zoledronic acid to prevent bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer [19]. Denosumab selectively inhibits RANKL, a primary mediator of the formation, resorptive function, and survival of osteoclasts. RANK/RANKL interactions lead to both differentiation and activation of osteoclasts, and the interaction of OPG with RANKL
negatively regulates this process. In this study, we observed significant differences in the serum concentration of RANKL and the ratio of RANKL/OPG during AI therapy between cases and controls, suggesting that AI-related MS-AEs are associated with the RANKL/RANK/OPG bone remodeling pathway. Moreover, concentrations of the bone turnover markers CTX and PINP were elevated in the AI-related MS-AEs group compared with the control group. These results suggest that individuals with AI-related MS-AEs have a predisposition for higher bone resorption. The regulation of bone mass is governed by a complex interplay between bone-forming cells termed osteoblasts and bone-resorbing cells termed osteoclasts [20]. Osteoclast activation, which can lead to bone pain, fracture and other musculoskeletal problems, is induced by RANKL and suppressed by OPG.

Multiple factors influence the levels of RANKL and OPG. Smoking is one factor that affects the expression of RANKL and OPG; patients who are cigarette smokers tend to have lower serum concentrations of RANKL and OPG than non-smoking patients [21]. In our study, no significant difference was observed between the case group and control group based on smoking status. In addition to smoking, hormones can also influence the levels of RANKL and OPG; estrogen (and androgen) increases OPG secretion from osteoblasts, decreases the ratio of RANKL to OPG, downregulates the expression of RANKL on osteoclasts, and inhibits overall bone resorption [22,23]. Conversely, when estrogen and androgen levels decrease either as a consequence of normal menopause and aging or due to the effects of cancer treatments (AIs, chemotherapy, gonadotropin-releasing agonists, and androgen-deprivation therapy [ADT]), RANKL levels increase, and OPG levels decrease, which causes net bone resorption. In this study, a significant decrease was observed in mean estradiol levels in the AI-related MS-AEs group compared with the control group. Estradiol concentrations in postmenopausal women with early stage, ER-positive breast cancer who received anastrozole therapy significantly decreased over 24 months [24]. In contrast, levels of the serum bone turnover markers CTX and PINP increased significantly in the first 12 months of anastrozole treatment. One possible explanation for AI-related MS-AEs could be the presence of secondary bone disorders caused by decreases in the serum estradiol levels. However, not every patient treated with AIs develops these side effects, suggesting that some individuals may be predisposed to the negative skeletal effects of AIs [25]. Many studies have identified genetic variants in the RANKL, RANK, and
OPG genes that are associated with bone mineral density and the risk for bone fractures [16,26]. Therefore, we hypothesized that SNPs related to markers of bone and joint health may contribute to AI-related MS-AEs.

We examined 29 SNPs using the “Tagger” program and data from the international HapMap project to investigate the relationship between RANKL/RANK/OPG polymorphisms and AI-related MS-AEs. Circulating T cells in the blood display detectable polymorphisms, and sufficient frequency differences in the alleles can be detected. Blood samples are easier to collect than tumor tissues and bone marrow; therefore, we detected the RANKL, RANK and OPG polymorphisms in easily accessible peripheral blood samples. We found that the SNPs rs7984870 of RANKL and rs2073618 of OPG were significantly associated with AI-related MS-AEs; however, we failed to find any significant association between any phenotype and RANK polymorphisms. Neither of these two SNPs had been tested previously in association with AI-related MS-AEs, but they had been associated previously with other bone diseases, such as rheumatoid arthritis (RA), osteonecrosis and fractures. Previous studies have reported that the rs7984870 SNP was consistently associated with an earlier age of RA onset in 3 independent seropositive (RF or anti-cyclic citrullinated peptide antibody positive) RA cohorts but not in seronegative RA patients [27]. Some of the OPG SNPs (rs10505348, rs2073617 and rs2073618) have previously been found to correlate with lumbar spine BMD in a large GWAS meta-analysis, with significance at the genome-wide level [28,29]. In addition, another study of the OPG rs2073618 SNP (1181 G/C) describes a 26% higher risk of hip fractures and a 52% higher chance of femoral neck fractures in women with the CC homozygote than women with the GG homozygote, independent of BMD [17].

In this study, we found that women with the rs7984870 CC or rs2073618 CC genotypes were at risk for AI-related MS-AEs. They also experienced a greater increase in the levels of CTX and PINP, which suggests enhanced bone resorption. In addition, the rs2073618 CC risk genotype but not the rs7984870 CC risk genotype was associated with a significant reduction in BMD at the lumbar spine. Similarly, women with any risk genotypes (rs2073618 CC or rs7984870 CC) of AI-related MS-AEs had a higher prevalence of osteoporosis and osteopenia than women with no risk genotypes. Similar results have been reported in another study; the minor allele of rs2073618 (C) was associated with higher levels of both PINP and CTX-I and a lower lumbar spine BMD [28]. Compared with the controls, a significant decrease in the mean estradiol levels was found in the AI-related MS-AEs group, but no significant differences in estradiol levels were observed between women with the risk genotypes or no risk genotypes. The profound estrogen deficiency induced by AIs is believed to account for the increased bone loss, fractures and incidence of musculoskeletal pains. Our findings in the current study confirmed that women with the risk genotypes could be more sensitive to hormonal manipulation than women with the no risk genotypes.

The association between serum levels of OPG and soluble RANKL and their gene polymorphisms has been investigated in several studies [30–32]. The risk C allele of rs7984870 has been reported to confer a 2-fold higher level of plasma soluble RANKL in RF+ RA patients and significantly elevated mRNA expression of RANKL isoform1 by activated control T cells. Furthermore, this study suggested that the minor C allele of rs7984870 creates a binding site for the transcription factor SOX5, which may influence bone metabolism and RANKL transcription [27]. Our study had a similar outcome; the risk CC genotype of rs7984870 conferred a higher plasma soluble RANKL level and RANKL/OPG ratio. In addition, a study of a Chinese population showed that the Asn-Asn genotype of rs2073618 is associated with lower serum OPG levels compared with the Lys-Lys genotype [30], which is consistent with our finding that the C allele of rs2073618 is associated with lower serum OPG levels and a higher RANKL/OPG ratio. Moreover, a significant correlation was observed between the ratio of RANKL/OPG and BMD.
in the AI-related MS-AEs group. OPG acts as a decoy receptor and blocks the effects of RANKL. RANKL increases the production, activity, and survival of osteoclasts [12]. Therefore, SNPs that lead to the decreased activity of OPG would be expected to have a negative impact on bone health due to increased bone resorption.

Following one year of aromatase inhibitor therapy, a 56-year-old breast cancer patient presented with widespread osteoarthralgia, and serum analysis showed increased expression of RANKL and an altered distribution of Th1/Th2 lymphocytes [33]. Another study indicated that IL17RA may also increase in patients with severe musculoskeletal symptoms after therapy with aromatase inhibitors [34]. Considering the role of estrogen in the immune system, we also tested the expression of some pro- and anti-inflammatory markers in our study. In contrast to our original hypothesis, we observed no significant differences in the serum concentrations of inflammatory markers during AI therapy between cases and controls. This result is similar to the findings of another study [35]. However, we cannot exclude the possibility that AI-related MS-AEs are due to a systemic inflammatory response. Other studies have suggested that local inflammatory processes, such as tenosynovitis at the wrist, may be occurring, as demonstrated using magnetic resonance imaging, musculoskeletal sonography and electromyography [36,37]. Therefore, future studies should investigate the local concentration of inflammatory factors.

To summarize, these findings add to our knowledge of the role of genetic variation in the RANKL/RANK/OPG signaling pathway in AI-related MS-AEs. Increased levels of bone turnover markers and a higher RANKL/OPG ratio suggest disturbances between bone formation and resorption in patients with AI-related MS-AEs. Patients with the CC genotype of the RANKL rs7984870 SNP appeared to be at risk of having higher serum RANKL levels and a higher RANKL/OPG ratio, whereas the CC genotype of the OPG rs2073618 SNP was associated with lower serum OPG levels and a higher RANKL/OPG ratio. In both cases, a higher RANKL/OPG ratio may negatively impact bone health due to increased bone resorption. Furthermore, these two risk genetic variations in RANKL and OPG also affected bone turnover and BMD. We could not compare our data with other studies of AI-related MS-AEs because these two SNPs have not been investigated previously. Therefore, it will be important to carry out studies in larger cohorts of Chinese postmenopausal women and in different populations worldwide to confirm our results.

Supporting Information
S1 Fig. Linkage disequilibrium between genotyped SNPs of RANK (A), OPG (B) and RANKL (C).
(TIF)

S1 Table. Serum estradiol, CTX, PINP, OPG, RANKL concentration and BMD prior aromatase inhibitors treatments.
(DOC)

Acknowledgments
This experiment was finished in oncology key lab of Heilongjiang province institution of higher Education.

Author Contributions
Conceived and designed the experiments: QZ JW. Performed the experiments: JW KL YS LL SZ QX. Analyzed the data: JW KL SZ. Contributed reagents/materials/analysis tools: JW KL YS
SZ WM QX DT HZ LL. Wrote the paper: JW KL QZ. Specimen collection and manuscript preparation: WM DT WM.

References

1. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with estrogen-responsive early breast cancer: Update of study BIG 1–98. J Clin Oncol. 2007; 25:486–492. PMID: 17200148

2. Jonat W, Grant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006; 7:991–996. PMID: 17138220

3. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008; 26:1948–1955. doi: 10.1200/JCO.2007.11.6798 PMID: 18332475

4. Melton LJ, Hartmann LC, Achenbach SJ, Atkinson EJ, Therneau TM, Khosla S. Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res. 2012; 27(5):1196–1205. doi: 10.1002/jbmr.1556 PMID: 22358822

5. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists’ group. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006; 21(8):1215–1223. PMID: 16869719

6. Santen R. Effect of Endocrine Therapies on Bone in Breast Cancer Patients. J Clin Endocrinol Metab. 2011; 96(2):308–319. doi: 10.1210/jc.2010-1679 PMID: 21477885

7. Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, et al. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat. 2012; 133(2):685–693. doi: 10.1007/s10549-012-1973-0 PMID: 22307266

8. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, et al. Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer. 2014; 120:381–389. doi: 10.1002/cncr.28352 PMID: 24375332

9. Oh B, Kimble B, Costa DS, Davis E, McLean A, Orme K, et al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study. Acupunct Med. 2013; 31:264–271. doi: 10.1136/acupmed-2012-010309 PMID: 23722951

10. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Research and Treatment. 2009; 118(1):81–87. doi: 10.1007/s10549-009-0352-y PMID: 19308727

11. Baudhuin M, Duplomb L, Ruiz VC, Fortun Y, Heymann D, Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther. 2007; 7:221–232. PMID: 17288531

12. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9 Suppl 1: S1. PMID: 17634140

13. Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012; 27(3):495–505. doi: 10.1002/jbmr.1547 PMID: 22358489

14. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2):139–146. doi: 10.1016/j.abb.2008.03.018 PMID: 18395508

15. Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012; 18(2):326–335. doi: 10.1158/1078-0432.CCR-10-2507 PMID: 22031096

16. Piedra M, García-Unzueta MT, Berja A, Paule B, Lavin BA, Valero C, et al. "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". BMC Med Genet. 2011; 12:168. doi: 10.1186/1471-2350-12-168 PMID: 22185226

17. Moffett SP, Oakley JI, Cauley JA, Lui LY, Ensrud KE, Taylor BC, et al. Study of Osteoporotic Fractures Research Group. Study of Osteoporotic Fractures Research Group. Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women. J Clin Endoc Metab. 2008; 93:2002–2008.
18. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol. 2008; 26:2874–2882.

19. Rivadeneira F, Styrkársdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009; 41:1199–1206. doi: 10.1038/ng.446 PMID: 19801982

20. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ,Douglal WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012; 11:40.

21. Lappin DF, Sherrabeh S, Jenkins WM, Macpherson LM. Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive therapy periodontitis patients. J Periodontol. 2007; 34:271–277. PMID: 17378883

22. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003; 32:136–141. PMID: 12633785

23. Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res. 2004; 36:674–678. PMID: 15523951

24. Kyvernitakis I, Knöll D, Struck M, Hars O, Bauer T, Hadji P. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with early breast cancer treated with aromatase inhibitor. J Cancer Res Clin Oncol. 2014; 140:159–166. doi: 10.1007/s00432-013-1557-3 PMID: 24292402

25. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer. 2010; 103(3):291–296. doi: 10.1038/sj.bjc.6605786 PMID: 20666883

26. Zhao HY, Liu JM, Ning G, Zhao YJ, Zhang LZ, Sun LH, et al. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporos Int. 2005; 16:1519–1524. PMID: 15782282

27. Kim JG, Kim JH, Kim YJ, Ku SY, Jee BC, Sun LH, et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause. 2007; 14(5):913–918. PMID: 17667143

28. Jergensen HL, Kusk P, Madsen B, Fenger M, Laurantzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab. 2004; 22:132–138. PMID: 14999524

29. Bruzzese V, Hassan C, Zullo A, Zampa G. Rheumatoid arthritis: a complication of aromatase inhibitor therapy? Int J Immunopathol Pharmacol. 2011; 24(4):1099–1101. PMID: 22230418

30. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, et al. Genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010; 28(31):4674–4682. doi: 10.1200/JCO.2010.28.5064 PMID: 20876420

31. Henry NL, Pchejetski D, A’Hern R, Nguyen AT, Charles P, Waxman J, et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer. 2010; 103(3):291–296. doi: 10.1038/sj.bjc.6605786 PMID: 20666883

32. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, et al. Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor-Associated Arthralgia Syndrome. J Clin Oncol. 2008; 26:3147–3152. doi: 10.1200/JCO.2007.15.4005 PMID: 18474874

33. Dizdar O, Ozçakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-associated arthralgia. J Clin Oncol. 2009; 27(30):4955–4960. doi: 10.1200/JCO.2008.20.5435 PMID: 19752344